Tirzepatide
Mounjaro / Zepbound — weekly injection
Overview
Dual GIP+GLP-1 receptor agonist. The most effective weight loss medication currently available, showing 15–22% average body weight reduction in clinical trials. FDA approved for type 2 diabetes (Mounjaro) and obesity (Zepbound).
Key Benefits
- ✓15–22% average body weight loss
- ✓Dual GIP+GLP-1 receptor mechanism
- ✓Blood sugar regulation
- ✓Cardiovascular protective effects
- ✓Significant reduction in hunger and cravings
Dosing Protocol
How to Use
Advance dose every 4 weeks if well tolerated. Nausea most common in weeks 1–8 and typically improves. Never skip titration steps.
Titration Schedule
Follow this stepwise dose advancement. Never skip a step.
- Week 12.5mgStarting dose
- Week 55mgTitration 1
- Week 97.5mgTitration 2
- Week 1310mgTitration 3
- Week 1712.5mgTitration 4
- Week 2115mgMaintenance
The Science
This compound has FDA-backed clinical evidence — review the trial data and prescribing information below.
Get a Prescription
Prescription Required
TelehealthGLP-1 medications require a prescription. Connect with a licensed telehealth provider to get started.
STACK does not sell, prescribe, or dispense medications.
Track Tirzepatide with the STACK app
Set dose reminders, monitor your supply, and ask AI questions about your protocol — all in one place.
All content is for informational purposes only. Peptides are research compounds. Consult a licensed healthcare provider before starting any protocol.
STACK may earn a commission when you purchase through our links at no extra cost to you. This never influences our recommendations — we only feature vendors with verified third-party testing and established quality standards.